Desmopressin acetate will also stop bleeding in mild to moderate von Willebrand’s disease patients with episodes of spontaneous or trauma-induced injuries such as hemorrhages, intramuscular hematomas, mucosal bleeding or menorrhagia.11

In the outpatient setting during two clinical trials where patients recorded bleeding episodes, Stimate® (desmopressin acetate) Nasal Spray provided effective hemostasis 100% of the time in 75% of the patients (n=16). For those patients not responding in 100% of bleeding occasions, 78% (7 of 82) of bleeding episodes were effectively controlled with Stimate® Nasal Spray. Patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and Factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked after initial administration of Stimate® Nasal Spray to ensure that adequate levels have been achieved.

Stimate® Nasal Spray is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of Factor VIII antigen. See WARNINGS.

CONTRAINDICATIONS

Stimate® Nasal Spray is contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of Stimate® Nasal Spray.

WARNINGS

For intranasal use only.

Patients who do not have need of antidiuretic hormone for its antidiuretic effect, in particular those who are young or elderly, should be cautioned to ingest only enough fluid to satisfy thirst, in order to decrease the potential occurrence of water intoxication and hyponatremia.

 Fluid intake should be adjusted downward, particularly in very young and elderly patients, in order to decrease the potential occurrence of water intoxication and hyponatremia.11

Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality, and a corresponding mild increase in brain volume, which could lead to coma.

Stimate® Nasal Spray should not be used to treat patients with type IB von Willebrand’s disease since platelet aggregation may be induced.

PRECAUTIONS

General

Desmopressin acetate has infrequently produced changes in blood pressure causing either a slight elevation in blood pressure or a transient fall in blood pressure and a compensatory increase in heart rate. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

Stimate® Nasal Spray should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, because these patients are prone to hyponatraemia.

There have been rare reports of thrombotic events (thrombosis), acute cerebrovascular thrombosis, acute myocardial infarction following desmopressin acetate injection in patients predisposed to thrombus formation. No causality has been determined, however, the drug should be used with caution in these patients.

Severe allergic reactions have been reported rarely.11,16,17 Fatal anaphylaxis has been reported in one patient who received intravenous DDAVP® (desmopressin acetate). It is not known whether antibodies to desmopressin acetate are produced after repeated administration.

Stimate® Nasal Spray is not recommended for use in patients with mild hemophilia A and von Willebrand’s disease (Type I) with Factor VIII levels greater than 5%.

Plasminogen activator activity increases rapidly after intravenous desmopressin acetate infusion, but there has been no clinically significant fibrinolysis in patients treated with desmopressin acetate.

The effect of repeated intravenous desmopressin acetate administration when doses were given every 12 to 24 hours has generally shown a diminution of the Factor VIII activity increase noted after a single dose. It is possible to reproduce the initial response in some patients after an interval of 1 to 2 weeks.18

The half-life of Stimate® Nasal Spray was between 3.3 and 3.5 hours, over the range of intranasal dosages, 150 to 450 µg. Plasma concentrations of Stimate® Nasal Spray were maximal approximately 40 to 45 minutes after dosing.1

The bioavailability of Stimate® Nasal Spray when administered by the intranasal route as a 1.5 mg/mL solution is between 3.3 and 4.1 percent.1

The change in structure of arginine vasopressin to desmopressin acetate has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.

INDICATIONS AND USAGE

In the subcutaneous therapeutic administration of Stimate® Nasal Spray, the physician should establish that the patient shows an appropriate change in the coagulation profile following a test dose of intranasal administration of Stimate® Nasal Spray.1

Desmopressin acetate is also available as a solution for injection (DDAVP® Injection) where the intravenous route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness.

Hemophilia A

Stimate® Nasal Spray is indicated for patients with hemophilia A with Factor VIII coagulant activity levels greater than 5%. Desmopressin acetate will also stop bleeding in patients with hemophilia A with episodes of spontaneous or trauma-induced injuries such as hemorrhages, intramuscular hematomas or mucosal bleeding.11

In the outpatient setting during two clinical trials where patients recorded bleeding episodes, Stimate® Nasal Spray provided effective hemostasis 100% of the time in 2 of the 5 patients. For those patients not responding in 100% of bleeding occasions, 45% (14 of 31) of bleeding episodes were effectively controlled with Stimate® Nasal Spray. Desmopressin acetate is not indicated for the treatment of hemophilia A with Factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have Factor VIII antibodies.

von Willebrand’s Disease (Type I)

Stimate® Nasal Spray is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with Factor VIII levels greater than 5%.
PATIENT INSTRUCTION GUIDE

Stimate® (desmopressin acetate)
Nasal Spray, 1.5 mg/mL

A better way to deliver desmopressin acetate

Delivering desmopressin acetate more efficiently

Your doctor has prescribed Stimate® Nasal Spray for the treatment of mild hemophilia A or mild to moderate von Willebrand’s disease (Type I). Follow the dosage schedule that is specified. The convenient nasal spray pump provides an efficient, reliable way to administer your medication. It is important, however, to adhere completely to the following instructions so that you will always receive a consistent dose of your medication.

CAUTION: The nasal spray pump accurately delivers 25 doses of 150 micrograms per spray. Any solution remaining after 25 sprays should be discarded since the amount delivered thereafter per spray may be substantially less than 150 micrograms of drug. Do not transfer any remaining solution to another bottle. Please read the following instructions carefully before using the spray pump.

Using your Stimate® Nasal Spray Pump

1. Remove protective cap.
2. When using for the first time, the spray pump must be primed by pressing down 4 times.
3. Once primed, the spray pump delivers 150 micrograms of medication each time it is pressed. To ensure dosing accuracy, tilt bottle so that dip tube inside the bottle draws from the deepest portion of the medication.

To administer a 150-microgram dose, place the spray nozzle in nostril and press the spray pump once. If a 300-microgram dose has been prescribed, spray once in each nostril. The spray pump cannot be used for doses less than 150 micrograms or doses other than multiples of 150 micrograms.

4. Replace the protective cap on bottle after use, and store in refrigerator. The pump will stay primed for up to one week under refrigeration. If the product has not been used for a period of one week, re-prime the pump before pressing once.
5. We have included a convenient check-off chart to assist you in keeping track of medication sprays used. This will help assure that you receive 25 “full sprays” of medication. Please note that the bottle has been filled with extra solution to accommodate the priming activity. When checking off sprays used, do not include the priming sprays.

Stimate® (desmopressin acetate)
Nasal Spray, 1.5 mg/mL
25-Spray Check-off

1 2 3 4 5
6 7 8 9 10
11 12 13 14 15
16 17 18 19 20
21 22 23 24 25

1. Retain with medication or affix in convenient location, e.g., refrigerator.
2. Starting with spray #1, check off each after administration. If your doctor has prescribed a 2-spray dose (300-micrograms), two sprays must be checked off.
3. Discard medication after 25 sprays.

KEEP REFRIGERATED AT 2-8°C (36-46°F).

When traveling, product will maintain stability for up to 3 weeks when stored at room temperature, 22°C (72°F).